Know Cancer

or
forgot password

Influence of Hyperandrogenemia on the Sleep-associated Slowing of Follicular LH Frequency in Adult Polycystic Ovary Syndrome


N/A
18 Years
35 Years
Open (Enrolling)
Female
Polycystic Ovary Syndrome

Thank you

Trial Information

Influence of Hyperandrogenemia on the Sleep-associated Slowing of Follicular LH Frequency in Adult Polycystic Ovary Syndrome


During the follicular phase of the normal menstrual cycle, luteinizing hormone (LH) pulse
frequency decreases during sleep. These decreases may be important to support follicle
stimulating hormone (FSH) synthesis and secretion. Polycystic ovary syndrome (PCOS) is
associated with a persistently rapid gonadotropin hormone-releasing hormone (GnRH) pulse
frequency, an abnormality that may account for many of the hormonal manifestations of PCOS.
Although one prior study suggests that nocturnal LH frequency decreases slightly in PCOS,
methodological issues limit interpretation. Our preliminary data suggest that nocturnal LH
frequency does not decrease in untreated PCOS, but that nocturnal decreases of LH frequency
are restored with androgen receptor blockade (flutamide) in women with PCOS. We have two
hypotheses: (1) Prior to flutamide administration, sleep-associated slowing of LH pulse
frequency is less pronounced in women with PCOS compared to that of normally-cycling women
in the late follicular phase of the menstrual cycle; (2) After 4 weeks of flutamide
administration, sleep-associated LH frequency reduction in women with PCOS is similar to
that of normally-cycling women in the late follicular phase of the menstrual cycle. Women
with PCOS and normally-cycling women will be studied. For each study participant, LH pulse
frequency will be determined (from 1500 to 0700 h) after 4 weeks of flutamide and after 4
weeks of placebo. Flutamide and placebo will be given in random order (i.e., cross-over
study). Sleep will be formally evaluated. Flutamide will then be given for 4 weeks prior to
reassessment of LH pulse frequency. LH pulse frequency will be analyzed by way of
hierarchical mixed effect models. We will use statistical analyses to determine: (a) whether
the wake vs. sleep difference in LH frequency is the same for PCOS and normal controls prior
to flutamide, and (b) whether the mean wake vs. sleep difference in LH frequency is the same
for the two groups after flutamide.


Inclusion Criteria:



Inclusion criteria for all participants:

- Subjects will be 18-35 years old; we use a cutoff age of 35 y because early menopause
at this age is very rare.

- No significant health problems (other than PCOS and obesity).

- Subjects will be willing to strictly avoid pregnancy (using non-hormonal methods)
during the time of study and must be willing and able to provide informed consent.

Inclusion criteria for normal controls:

- Controls will be healthy women with regular menstrual cycles and no evidence of
hyperandrogenism.

Inclusion criteria for PCOS:

- PCOS will be defined according to NIH consensus criteria.

- As such, subjects with PCOS will have hyperandrogenism, whether it is clinical
(e.g., hirsutism) or biochemical (i.e., elevated plasma T).

- Subjects with PCOS will also have oligo- or amenorrhea (i.e., < 7 periods per
year) and no evidence for other endocrinopathies (e.g., hyperprolactinemia,
Cushing's syndrome, etc.).

Exclusion Criteria:

- Being a study of GnRH pulse regulation in women with and without PCOS, men are
excluded.

- Obesity associated with a diagnosed (genetic) syndrome, obesity related to
medications (e.g., glucocorticoids), etc.

- Pregnancy or lactation.

- Virilization.

- A total testosterone > 150 ng/dl in women with PCOS (which suggests the possibility
of a virilizing neoplasm) (confirmed on repeat).

- Elevated DHEAS (mild elevations may be seen in PCOS, and elevations < 1.5 times the
upper limit of normal will be accepted in PCOS)(confirmed on repeat).

- Follicular 17-hydroxyprogesterone > 300 ng/dl, which suggests the possibility of
congenital adrenal hyperplasia (if elevated during the luteal phase and there is a
concern about the possibility of congenital adrenal hyperplasia, the
17-hydroxyprogesterone may be collected during the follicular phase, or >60 if
oligomenorrheic).

*NOTE: If a 17-hydroxyprogesterone > 300 ng/dl is confirmed on such repeat testing,
an ACTH stimulated 17-hydroxyprogesterone < 1000 ng/dl will be required for study
participation.

- A previous diagnosis of diabetes, a fasting glucose ≥ 126 mg/dl, or a hemoglobin A1c
> 6.5%

- Abnormal TSH (subjects with adequately treated hypothyroidism, reflected by normal
TSH values, will not be excluded; or, for a new diagnosis of hypothyroidism, further
study will at the least be delayed pending appropriate treatment) (confirmed on
repeat).

- Abnormal prolactin (mild elevations may be seen in PCOS, and elevations < 1.5 times
the upper limit of normal will be accepted in this group) (confirmed on repeat).

- Evidence of Cushing's syndrome by history or physical exam.

- Hematocrit < 36% or hemoglobin < 12 g/dl (that is not reversed by iron treatment).

- Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected
congestive heart failure; asthma requiring intermittent systemic corticosteroids;
etc.)

- Liver test abnormalities (confirmed on repeat), with the exception that mild
bilirubin elevations will be accepted in the setting of known Gilbert's syndrome.

- Abnormal sodium or potassium (confirmed on repeat); bicarbonate concentration <20 or
>30 (confirmed on repeat); or elevated creatinine concentration (confirmed on
repeat).

- Due to the amount of blood being drawn in the study, subjects with body weight < 110
lbs will be excluded from the study.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)

Outcome Measure:

Luteinizing hormone pulse frequency

Outcome Time Frame:

One and two months

Safety Issue:

No

Principal Investigator

Christopher R McCartney, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Virginia

Authority:

United States: Food and Drug Administration

Study ID:

14067

NCT ID:

NCT00930228

Start Date:

January 2009

Completion Date:

January 2014

Related Keywords:

  • Polycystic Ovary Syndrome
  • Luteinizing hormone
  • Testosterone
  • Polycystic Ovary Syndrome

Name

Location

University of VirginiaCharlottesville, Virginia  22908